Clomifene
202px | |
Systematic (IUPAC) name | |
---|---|
2-(4-(2-chloro-1,2-diphenylethenyl) phenoxy)-N,N-diethyl-ethanamine | |
Clinical data | |
Pregnancy category | |
Routes of administration | 50 mg tablets |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | High (>90%) |
Metabolism | Hepatic (with enterohepatic circulation) |
Biological half-life | 5-7 days |
Excretion | Mainly renal, some biliary |
Identifiers | |
CAS Number | 911-45-5 |
ATC code | G03GB02 (WHO) |
PubChem | CID 1548953 |
DrugBank | APRD00880 |
ChemSpider | 1265967 |
Chemical data | |
Formula | C26H28ClNO |
Molar mass | 406 or 598.10 (with citrate)[[Script error: No such module "String".]] |
Script error: No such module "collapsible list". | |
(verify) |
Clomifene (INN) or clomiphene (USAN and former BAN) or Clomid or Clomifert is a selective estrogen receptor modulator (SERM) that increases production of gonadotropins by inhibiting negative feedback on the hypothalamus. It is used mainly for ovarian stimulation in female infertility due to anovulation (e.g., due to polycystic ovary syndrome). Clomiphene citrate is marketed under various trade names including Clomid, Serophene, and Milophene.
Contents
Mode of action
In normal physiologic female hormonal cycling, at 7 days past ovulation, high levels of estrogen and progesterone cause negative feedback inhibition at the hypothalamus and anterior pituitary. As a result, decreased LH levels leads to atrophy of the corpus luteum, subsequently leading to decreased production of estrogen and progesterone. This will release the feedback inhibition of the hypothalamus and anterior pituitary, causing the FSH level to rise again at day 22.
Therapeutically, clomiphene is given at day 2 of menses. By that time, FSH level is rising steadily, causing development of a few follicles. Follicles in turn produce the estrogen, which circulates in serum. Clomiphene acts by inhibiting the action of estrogen on the pituitary. Zuclomifene, the more active isomer (see below), binds to estrogen receptors and stays bound for long periods of time. This prevents normal receptor recycling and causes an effective reduction in hypothalamic estrogen receptor number. As a result, the body perceives a low level of estrogen, similar to day 22 in the previous cycle. Since estrogen can no longer effectively exert negative feedback on the hypothalamus, GnRH secretion becomes more pulsatile, which results in increased pituitary gonadotropin (FSH, LH) release. Increased FSH level causes growth of more ovarian follicles, and subsequently rupture of follicles resulting in ovulation.
Chemistry
Clomifene is a mixture of two geometric isomers, enclomifene (E-clomifene) and zuclomifene (Z-clomifene).
Adverse effects
Common adverse drug reactions associated with the use of clomifene (≥1% of patients) include: vasomotor flushes (or hot flashes ), abdominal discomfort, visual blurring (dose-dependent), and/or reversible ovarian enlargement and cyst formation. Infrequent adverse effects (0.1–1% of patients) include: abnormal uterine bleeding, nausea, and/or vomiting. Rare adverse effects (<0.1% of patients) include: reversible alopecia and/or ovarian hyperstimulation syndrome.[1]
Clomiphene can lead to multiple ovulation, hence increasing the chance of twins (10% of births instead of the normal ~1%). In comparison to treatment with purified FSH, the rate of ovarian hyperstimulation syndrome is low. There may be an increased risk of ovarian cancer and weight gain. Some patients may experience vivid and/or disturbing dreams.
Illegal use in bodybuilding and other sports
Clomifene is commonly used by male anabolic steroid users to bind the estrogen receptors in their bodies, thereby blocking the effects of estrogen, such as gynecomastia. It also restores the body's natural production of testosterone. It is commonly used as a "recovery drug" and taken toward the end of a steroid cycle.[citation needed] It is included on the World Anti-Doping Agency list of illegal doping agents in sport.[2] Some users report that taking Clomid increases the amount of fluid produced during ejaculation, which make it a fertility drug option for men as well.
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
External links
de:Clomifenfa:کلومیفن سیترات fr:Clomiphène it:Clomifene nl:Clomifeen
pt:Clomifeno- ↑ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3
- ↑ The WADA Prohibited List
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- All articles with unsourced statements
- Articles with unsourced statements from June 2008
- Articles with invalid date parameter in template
- 2Fix
- Citrates
- Selective estrogen receptor modulators
- Stilbenoids
- Phenol ethers
- Organochlorides